A Double-Blind, Randomised, Placebo-controlled, Cross-over, Phase 2 Mannitol Challenge Trial, Investigating the Efficacy of CRD007 in Adult Subjects With Asthma

Trial Profile

A Double-Blind, Randomised, Placebo-controlled, Cross-over, Phase 2 Mannitol Challenge Trial, Investigating the Efficacy of CRD007 in Adult Subjects With Asthma

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2016

At a glance

  • Drugs Pemirolast (Primary)
  • Indications Asthma
  • Focus Pharmacodynamics
  • Sponsors RSPR Pharma
  • Most Recent Events

    • 18 May 2016 Primary endpoint has been met. (PD15 for 400 mg CRD007 versus 40 mg CRD007 and placebo), as per results presented at the 112th International Conference of the American Thoracic Society.
    • 18 May 2016 Results presented at the 112th International Conference of the American Thoracic Society
    • 25 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top